COVID-19 - November 30, 2020
Exclusive interview: William A. Haseltine
Nordic Life Science got an exclusive chance to ask scientist, businessman and philanthropist William A. Haseltine, well known for his pioneering work in cancer, HIV/AIDS and genomics, about his views on the COVID-19 pandemic. William A. Haseltine, PhD, (born 1944) is an American scientist, businessman, author and philanthropist. He has been a professor at Harvard […]
COVID-19 - November 30, 2020
New findings on how the new coronavirus infects cells
A German-Finnish team of researchers has discovered the second ‘key’ used by the SARS-CoV-2 virus to enter into human cells. To efficiently infect human cells, SARS-CoV-2 is able to use a receptor called Neuropilin-1, which is very abundant in many human tissues including the respiratory tract, blood vessels and neurons, state the researchers. The research […]
COVID-19 - November 23, 2020
AstraZeneca’s vaccine met primary efficacy endpoint
Positive high-level results from an interim analysis of clinical trials of AZD1222 in the UK and Brazil showed the vaccine was highly effective in preventing COVID-19, the primary endpoint, and no hospitalizations or severe cases of the disease were reported in participants receiving the vaccine. There were a total of 131 COVID-19 cases in the […]
COVID-19 - November 19, 2020
New results from in vitro combination therapy against COVID-19
Researchers at Karolinska Institutet report promising results from an in vitro combination therapy against COVID-19. In a study published in EMBO Molecular Medicine, the researchers show that a combination of remdesivir, an approved drug against COVID-19, and hrsACE2, a medicine currently in phase II trials for COVID-19 treatment, reduced the viral load of SARS-CoV-2 and […]
COVID-19 - November 19, 2020
Interim results from AstraZeneca’s COVID-19 vaccine trial
Interim results from the ongoing Phase II/III COV002 trial of AZD1222 in the UK, led by the University of Oxford, demonstrated lower local and systemic reactions in older adults (≥56-69 years and ≥70 years) than younger adults (≥18-55 years) and generated similar robust immune responses against the SARS-CoV-2 virus across all adult age groups. “Generated […]
COVID-19 - November 19, 2020
Pfizer and BioNTech conclude phase 3 study of COVID-19 vaccine candidate
Pfizer and BioNTech has announced that, after conducting the final efficacy analysis in their ongoing Phase 3 study, their mRNA-based COVID-19 vaccine candidate, BNT162b2, met all of the study’s primary efficacy endpoints. Analysis of the data indicates a vaccine efficacy rate of 95% (p<0.0001) in participants without prior SARS-CoV-2 infection (first primary objective) and also […]
